FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting


The FDA sent a rejection letter to Eli Lilly And Co LLY regarding its anti-PD-1 antibody sintilimab for the first-line treatment of nonsquamous non-small cell lung cancer.

  • The complete response letter (CRL) follows a nearly unanimous Oncologic Drugs Advisory Committee (ODAC) recommendation against sintilimab's approval. 
  • The CRL includes a recommendation for an additional clinical study, specifically a multiregional clinical trial comparing standard of care therapy for first-line metastatic NSCLC to sintilimab with chemotherapy utilizing a non-inferiority design with an overall survival endpoint.
  • Read Next: Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease.
  • As far as the next steps for sintilimab, which is approved in China, Lilly said it's assessing the situation with Innovent Biologics Inc IVBXF on the U.S. market.
  • Price Action: LLY shares are up 0.84% at $286.57 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!